Chemical Compound

1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-; 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]- (9CI); (R)-8-[3-Aminopiperidin-1-yl]-7-(2-butynyl)-3-methyl-1-(4-methylquinazolin-2-ylmethyl)xanthine; BI 1356; BI 1356BS; Linagliptin; ONDERO; Tradjenta; Trazenta

CAS Registry Number 668270-12-0
返回搜索 申请报价
1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-; 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]- (9CI); (R)-8-[3-Aminopiperidin-1-yl]-7-(2-butynyl)-3-methyl-1-(4-methylquinazolin-2-ylmethyl)xanthine; BI 1356; BI 1356BS; Linagliptin; ONDERO; Tradjenta; Trazenta 结构式
Primary record

1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-; 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]- (9CI); (R)-8-[3-Aminopiperidin-1-yl]-7-(2-butynyl)-3-methyl-1-(4-methylquinazolin-2-ylmethyl)xanthine; BI 1356; BI 1356BS; Linagliptin; ONDERO; Tradjenta; Trazenta

库存
2,934 克
纯度
98.9 %
CAS
668270-12-0

化合物标识与属性

CAS
668270-12-0
PubChem CID
10096344
SMILES
CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
Canonical SMILES
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C

名称与同义词

  • Linagliptin
  • Tradjenta
  • Ondero
  • 668270-12-0
  • Trazenta
  • Trajenta
  • linagliptine
  • Linagliptina
  • ione
  • linagliptinum
  • Linaglitpin
  • BI-1356
  • Linagliptin (BI-1356)
  • BI 1356
  • Tradjenta (TN)
  • Ondero (TN)
  • Linagliptin S-Isomer
  • Linagliptin (Standard)
  • RefChem:5948
  • BI-1356-BS
  • LINAGLIPTIN [MI]
  • 3X29ZEJ4R2
  • LINAGLIPTIN [INN]
  • LINAGLIPTIN [JAN]
  • UNII-3X29ZEJ4R2
  • Linagliptin [USAN:INN]
  • BS 1356 BS
  • C25H28N8O2
  • LINAGLIPTIN [USAN]
  • MFCD14635356
  • D02EYG
  • BI-1356BS
  • LINAGLIPTIN [VANDF]
  • Linagliptin [USAN:INN:JAN]
  • CHEMBL237500
  • BI 1356 BS
  • BS-1356-BS
  • LINAGLIPTIN [MART.]
  • BI1356
  • LINAGLIPTIN [WHO-DD]
  • cc-405
  • CHEBI:68610
  • HSDB 8204
  • Linagliptin (BI-1356)?
  • MLS006010217
  • SCHEMBL160188
  • Linagliptin (JAN/USAN/INN)
  • DTXSID201021653
  • GTPL6318
  • orb1310851
  • Linagliptin - Bio-X trade mark
  • SCHEMBL29359185
  • BI 1356BS
  • A10BH05
  • AMY8953
  • EX-A076
  • GLYXAMBI COMPONENT LINAGLIPTIN
  • LINAGLIPTIN [ORANGE BOOK]
  • LTXREWYXXSTFRX-QGZVFWFLSA-N
  • BCPP000185
  • DTXCID801506661
  • GLXC-10521
  • BCP02462
  • MSK15589
  • ZINC3820029
  • TRIJARDY XR COMPONENT LINAGLIPTIN
  • BDBM50228403
  • EBC-13284
  • HY-10284R
  • NP2669
  • s3031
  • 1356, BI
  • 1-(1H-Indol-3-ylmethyl)-propylamine
  • AKOS015951179
  • AKOS015995251
  • AC-8761
  • ACN-028592
  • AN-2539
  • BCP9000854
  • CCG-269463
  • CS-0637
  • CS-O-30970
  • DB08882
  • FL24893
  • RL04547
  • CID10096344
  • NCGC00346655-01
  • NCGC00346655-02
  • NCGC00346655-08
  • AJ-45731
  • AS-35080
  • BL164627
  • CID 10096344
  • CID:10096344
  • DA-54932
  • HY-10284
  • SC-66358
  • SC-83230
  • SMR004701306
  • SID:283537495
  • AB0008009
  • AB1008521
  • A4034
  • FT-0670793
  • NS00098773
  • SW219813-1
  • X1062
  • (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
  • J2.712.937D
  • KS-00000765
  • A26901
  • D09566
  • Q-4491
  • AB01563307_01
  • AB01563307_03
  • EN300-6481354
  • 270L120
  • C568794
  • Q909745
  • BRD-K96550715-001-02-6
  • BRD-K96550715-001-03-4
  • BRD-K96550715-001-04-2
  • BRD-K96550715-003-01-4
  • (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
  • 1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-
  • D000069476
  • Z2235801970
  • (R)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
  • (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-ynyl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
  • 1H-Purine-2,6-dione,8-[(3R)-3-amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-
  • 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione
  • 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
  • 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
  • 1h-purine-2,6-dione, 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-
  • 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione
  • 8-[(3R)-3-amino-1-piperidyl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
  • 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
  • 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-2,3,6,7-tetrahydro-1H-purine-2,6-dione
  • 8-[(3r)-3-Aminopiperidin-1-Yl]-7-But-2-Yn-1-Yl-3-Methyl-1-[(4-Methylquinazolin-2-Yl)methyl]-3,7-Dihydro-1h-Purine-2,6-Dione
  • (R)-8-[3-Aminopiperidin-1-yl]-7-(2-butynyl)-3-methyl-1-(4-methylquinazolin-2-ylmethyl)xanthine
  • 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)xanthine
  • 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)aminopiperidin-1-yl)xanthine
  • 1-[(4-methyl-quinazolin-2yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R) amino-piperidin-1-yl]-xanthine
  • 1-[(4-Methylquinazolin-2-yl)-methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine
  • 1-[(4-Methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine
  • 1233245-11-8
  • 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-; 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]- (9CI); (R)-8-[3-Aminopiperidin-1-yl]-7-(2-butynyl)-3-methyl-1-(4-methylquinazolin-2-ylmethyl)xanthine; BI 1356; BI 1356BS; Linagliptin; ONDERO; Tradjenta; Trazenta
  • 668270-11-9
  • 8-((3R)-3-AMINOPIPERIDIN-1-YL)-7-(BUT-2-YN-1-YL)-3-METHYL-1-((4-METHYLQUINAZOLIN-2-YL)METHYL)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE
  • 8-[(3R)-3-Aminopiperidin-1-yl]-7-but-2-yn-1-yl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-d
  • 8-[(3R)-3-Aminopiperidin-1-yl]-7-but-2-yn-1-yl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-d ione
  • 8-[(3R)-3-Aminopiperidine-1-yl]-7-(2-butyne-1-yl)-3-methyl-1-(4-methylquinazoline-2-yl)methyl-3,7-dihydro-1H-purine-2,6-dione
  • 8-[(3R)-3-Aminopiperidine-1-yl]-7-(2-butynyl)-3-methyl-1-(4-methylquinazoline-2-ylmethyl)-3H,7H-purine-2,6-dione
  • 8-[(3R)-3-Aminopiperidine-1-yl]-7-(2-butynyl)-3-methyl-1-[(4-methylquinazoline-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
  • 8-[(3R)-3-Aminopiperidine-1-yl]-7-(2-butynyl)-3-methyl-1-[(4-methylquinazoline-2-yl)methyl]-7H-purine-2,6-dione
  • 8-[3(R)-aminopiperidin-1-yl]-7-(2-butynyl)-3-methyl-1-(4-methylquinazolin-2-ylmethyl)xanthine
  • Linagliptin; (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione